Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Robin Park, Fariha Eshrat, Mohammed Al‐Jumayli, et al.
Vaccines (2020) Vol. 8, Iss. 3, pp. 447-447
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 97
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
Andreas Koulouris, Christos Tsagkaris, V. Spyrou, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 387-401
Open Access | Times Cited: 90
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 371-378
Closed Access | Times Cited: 86
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1245-1251
Closed Access | Times Cited: 82
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Immunotherapy (2021) Vol. 13, Iss. 8, pp. 637-644
Closed Access | Times Cited: 80
The Immunology of Hepatocellular Carcinoma
Gbemisola Lawal, Yao Xiao, Amir A. Rahnemai‐Azar, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1184-1184
Open Access | Times Cited: 65
Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study
Jinliang Zhang, Xihao Zhang, Han Mu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 52
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
Qi Li, Mengran Cao, Guosheng Yuan, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 28
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment
Yanju Liu, Hongyuan Yang, Tian Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy
Valentina Cazzetta, Sara Franzese, Claudia Carenza, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2184-2184
Open Access | Times Cited: 28
Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma
Yizhou Wang, Feihong Song, Xiaofeng Zhang, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-28
Open Access | Times Cited: 18
Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma
Shasha Sun, Xiaodi Guo, Wendong Li, et al.
World Journal of Clinical Cases (2024) Vol. 12, Iss. 2, pp. 285-292
Open Access | Times Cited: 2
CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression
Qinglong Yang, Gang Wu
Gastroenterología y Hepatología (2021) Vol. 45, Iss. 10, pp. 742-752
Closed Access | Times Cited: 11
Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4036-4036
Open Access | Times Cited: 8
Extracellular Vesicles in the HCC Microenvironment: Implications for Therapy and Biomarkers
Le Cheng, Limin Zhang, Xiaoxiao Wang, et al.
Pharmacological Research (2024), pp. 107419-107419
Open Access | Times Cited: 1
Cellular based treatment modalities for unresectable hepatocellular carcinoma
Konstantinos Damiris, Hamza Abbad, Nikolaos Pyrsopoulos
World Journal of Clinical Oncology (2021) Vol. 12, Iss. 5, pp. 290-308
Open Access | Times Cited: 7
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, et al.
Expert Opinion on Drug Safety (2022) Vol. 22, Iss. 4, pp. 323-329
Closed Access | Times Cited: 4
Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma
Min Yao, Junling Yang, Defeng Wang, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 11, pp. 3321-3333
Open Access | Times Cited: 3
Non-surgical Treatment Options in Managing Recurrent Hepatocellular Carcinoma
Walaa Abdelhamed, Mohamed El‐Kassas
Gene Expression (2023) Vol. 22, Iss. 3, pp. 211-221
Open Access | Times Cited: 1
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
CAR-T cell therapy: breakthroughs, challenges and emerging horizons in cancer treatment
Rajeev Goel
International Journal of Research in Medical Sciences (2024) Vol. 12, Iss. 12, pp. 4829-4841
Open Access
Hepatocellular carcinoma stem cells, progression and therapy
Vijaya Nirmala Pangi
Elsevier eBooks (2022), pp. 97-107
Closed Access | Times Cited: 1
Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?
Alessandro Rizzo, Angela Dalia Ricci
Expert Review of Precision Medicine and Drug Development (2022) Vol. 7, Iss. 1, pp. 50-57
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top